Rp2.843.771,21
+Rp93.365,21(+3,39%)
*Data terakhir diperbarui: 2026-07-03 02:46 (UTC+8)
Pada 2026-07-03 02:46, Becton Dickinson & Co (BDX) dihargai di Rp2.843.771,21, dengan total kapitalisasi pasar sebesar Rp986,29T, rasio P/E 25,19, dan imbal hasil dividen sebesar 2,47%. Hari ini, harga saham berfluktuasi di antara Rp2.620.342,33 dan Rp2.855.464,35. Harga saat ini adalah 8,52% di atas titik terendah hari ini dan 0,40% di bawah titik tertinggi hari ini, dengan volume perdagangan 2,05M. Selama 52 minggu terakhir, BDX telah diperdagangkan antara Rp2.518.522,00 hingga Rp3.456.131,87, dan harga saat ini adalah -17,71% jauh dari titik tertinggi 52 minggu.
Statistik Utama BDX
Penutupan KemarinRp2.791.691,77
Kapitalisasi PasarRp986,29T
Volume2,05M
Rasio P/E25,19
Imbal Hasil Dividen (TTM)2,47%
Jumlah DividenRp18.888,92
EPS Terdilusi (TTM)4,05
Laba Bersih (FY)Rp30,18T
Pendapatan (FY)Rp392,87T
Tanggal Pendapatan2026-08-06
Estimasi EPS3,13
Estimasi PendapatanRp87,90T
Saham Beredar353,29M
Beta (1T)0.278
Tanggal Ex-Dividend2026-06-09
Tanggal Pembayaran Dividen2026-06-30
Tentang BDX
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
SektorHealthcare
IndustriMedical - Instruments & Supplies
CEOThomas E. Polen Jr.
Kantor PusatFranklin Lakes,NJ,US
Situs Resmihttps://www.bd.com
Karyawan (FY)72,00K
Pendapatan Rata-rata (1T)Rp5,45B
Pendapatan Bersih per KaryawanRp419,25M
Pelajari lebih lanjut tentang Becton Dickinson & Co (BDX)
Blog
After BDX Surges 215%: Privacy Sector Revival or Low Liquidity Pricing?Beldex (BDX) has surged over 215% in the past 30 days, pushing its market capitalization past $3.7 billion. However, its 24-hour trading volume remains extremely low.2026-05-29

Why Might a Phased Liquidity Upgrade Trigger Structural Repricing for BDX?As a blockchain network positioned around privacy infrastructure and cross-chain interoperability, BDX has long sought to balance exchange liquidity with ecosystem expansion.2026-03-03

BDX Token Price Prediction 2026: Can This Rising Privacy Coin Break Through? In-Depth AnalysisPrivacy has become an increasingly valuable asset in the digital age, and the Beldex project is dedicated to building the infrastructure to protect it.2026-01-28

FAQ Becton Dickinson & Co (BDX)
Berapa harga saham Becton Dickinson & Co (BDX) hari ini?
x
Becton Dickinson & Co (BDX) saat ini diperdagangkan di harga Rp2.843.771,21, dengan perubahan 24 jam sebesar +3,39%. Rentang perdagangan 52 minggu adalah Rp2.518.522,00–Rp3.456.131,87.
Berapa harga tertinggi dan terendah 52 minggu untuk Becton Dickinson & Co (BDX)?
x
Berapa rasio harga terhadap pendapatan (P/E) dari Becton Dickinson & Co (BDX)? Apa arti dari rasio tersebut?
x
Berapa kapitalisasi pasar Becton Dickinson & Co (BDX)?
x
Berapa laba per saham (EPS) kuartalan terbaru untuk Becton Dickinson & Co (BDX)?
x
Apakah Anda sebaiknya beli atau jual Becton Dickinson & Co (BDX) sekarang?
x
Faktor apa saja yang dapat memengaruhi harga saham Becton Dickinson & Co (BDX)?
x
Bagaimana cara beli saham Becton Dickinson & Co (BDX)?
x
Peringatan Risiko
Pasar saham melibatkan tingkat risiko dan volatilitas harga yang tinggi. Nilai investasi Anda dapat meningkat atau menurun, dan Anda mungkin tidak mendapatkan kembali seluruh jumlah yang diinvestasikan. Kinerja masa lalu bukan merupakan indikator yang andal untuk hasil di masa depan. Sebelum membuat keputusan investasi, Anda harus dengan cermat menilai pengalaman investasi, kondisi keuangan, tujuan investasi, dan toleransi risiko Anda, serta melakukan riset sendiri. Jika diperlukan, konsultasikan dengan penasihat keuangan independen.
Penafian
Konten di halaman ini disediakan hanya untuk tujuan informasi dan bukan merupakan saran investasi, saran keuangan, atau rekomendasi perdagangan. Gate tidak bertanggung jawab atas kerugian atau kerusakan yang diakibatkan oleh keputusan keuangan tersebut. Lebih lanjut, harap diperhatikan bahwa Gate mungkin tidak dapat menyediakan layanan penuh di pasar dan yurisdiksi tertentu, termasuk namun tidak terbatas pada Amerika Serikat, Kanada, Iran, dan Kuba. Untuk informasi lebih lanjut mengenai Lokasi Terbatas, silakan merujuk ke Perjanjian Pengguna.






